Alnylam Stock Rockets 50% as Trial Results Raise Hope for a Blockbuster
Barron's -

A highly anticipated late-stage trial of Alnylam Pharmaceutical s' drug Onpattro in a rare heart condition returned positive results, the company said, sending shares of the biotech up more than 50% in premarket trading. The results for the condition, ...

Related Articles

Latest in News

More from Barron's | Biotechnology Pharmaceuticals Healthcare Life Sciences Financial Performance Earnings Share Price Movement Disruptions New Products Services Research Development Corporate Industrial News Products New Product Service Testing Biology Political General News Sciences Humanities Content Types Factiva Filters C&E Exclusion Filter C&E Industry News Filter synd Biotech and Pharma Alnylam Pharmaceuticals ALNY Pfizer PFE SPDR S&P Biotech ETF XBI financial performance earnings share price movement disruptions new products services research development corporate industrial news products new product service testing biology biotechnology political general news sciences humanities content types factiva filters c&e exclusion filter c&e industry news filter biotech and pharma pharmaceuticals healthcare life sciences Patisiran Stock Amyloidosis Transthyretin Pharmaceutical industry Heart NASDAQ:ALNY